Reversion of pH-induced physiological drug resistance: A novel function of copolymeric nanoparticles

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Li, Rutian ^a   Xie, Li ^a   Zhu, Zhenshu ^b   Liu, Qin ^a   Hu, Yong ^b   Jiang, Xiqun ^b   Yu, Lixia ^a   Qian, Xiaoping ^a   Guo, Wanhua ^a   Ding, Yitao ^a   Liu, Baorui ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; DISULFIRAM; METHOXY POLYETHYLENEGLYCOL EPSILON CAPROLACTONE COPOLYMER; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZYLISOQUINOLINE DERIVATIVE; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL CO EPSILON CAPROLACTONE); METHOXY POLY(ETHYLENE GLYCOL-CO-EPSILON-CAPROLACTONE); POLYESTER; TETRANDRINE;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PH; CHEMICAL REACTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG MECHANISM; DRUG RELEASE; DRUG RESISTANCE; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PH; PH INDUCED PHYSIOLOGICAL DRUG RESISTANCE; PH MEASUREMENT; REVERSAL REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL STRAIN HEPG2; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; INSTITUTE FOR CANCER RESEARCH MOUSE; NEOPLASM; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZYLISOQUINOLINES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; POLYESTERS; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 80053152320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024172     Document Type: Article

References (32)

1. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, et al. (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23: 6019-6026.
2. Lee MJ, Veiseh O, Bhattarai N, Sun C, Hansen SJ, Ditzler S, et al. (2010) Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One 5: e9536.
3. Nishiyama N, (2007) Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2: 203-204.
4. Sanhai WR, Sakamoto JH, Canady R, Ferrari M, (2008) Seven challenges for nanomedicine. Nat Nanotechnol 3: 242-244.
5. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE, (2007) Characterization of nanoparticles for therapeutics. Nanomedicine 2: 789-803.
6. Hoffman AS, (2008) The origins and evolution of "controlled" drug delivery systems. J Control Release 132: 153-163.
7. Matsumura Y, (2008) Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 60: 899-914.
8. Tredan O, Galmarini CM, Patel K, Tannock IF, (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454.
9. Raghunand N, Altbach MI, van Sluis R, Baggett B, Taylor CW, et al. (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 57: 309-312.
10. Raghunand N, Gillies RJ, (2000) pH and drug resistance in tumors. Drug Resist Updat 3: 39-47.
11. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
12. Gerweck LE, Seetharaman K, (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56: 1194-1198.
13. Vukovic V, Tannock IF, (1997) Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 75: 1167-1172.
14. Raghunand N, Gillies RJ, (2001) pH and chemotherapy. Novartis Found Symp 240: 199-211.
15. Raghunand N, He X, van SR, Mahoney B, Baggett B, (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80: 1005-1111.
16. Wang Y, Bansal V, Zelikin AN, Caruso F, (2008) Templated synthesis of single-component polymer capsules and their application in drug delivery. Nano Lett 8: 1741-1745.
17. Lee CM, Tannock IF, (2006) Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br J Cancer 94: 863-869.
18. Hillaireau H, Couvreur P, (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896.
19. Rosen H, Abribat T, (2005) The rise and rise of drug delivery. Nat Rev Drug Discov 4: 381-385.
20. Li R, Li X, Xie L, Ding D, Hu Y, et al. (2009) Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm 379: 158-166.
21. Segal E, Pan H, Ofek P, Udagawa T, Kopecková P, et al. (2009) Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 4: e5233.
22. McCarron PA, Faheem AM, (2010) Nanomedicine-based cancer targeting: a new weapon in an old war. Nanomedicine 5: 3-5.
23. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, et al. (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23: 7785-7793.
24. Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, et al. (2006) Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer. Am J Clin Oncol 29: 267-275.
25. Zhu Z, Li Y, Li X, Li R, Jia Z, Liu B, et al. (2010) Paclitaxel-loaded poly(N-vinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 142: 438-446.
26. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, et al. (2009) A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30: 6006-6016.
27. Li X, Li R, Qian X, Ding Y, Tu Y, et al. (2008) Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 70: 726-734.
28. Minchinton AI, Tannock IF, (2006) Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
29. Rotin D, Wan P, Grinstein S, Tannock I, (1987) Cytotoxicity of compounds that interfere with the regulation of intracellular pH: a potential new class of anticancer drugs. Cancer Res 47: 1497-1504.
30. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
31. Kojima C, (2010) Design of stimuli-responsive dendrimers. Expert Opin Drug Deliv 7: 307-319.
32. Liu R, Li D, He B, Xu X, Sheng M, et al. (2011) Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles. J Control Release 152 (1): 49-56.